Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Covid save search
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
Published: 2024-02-21 (Crawled : 19:00) - biospace.com/
LGST | $4.51 -11.31% 13K
|
n/a
| Email alert
Add to watchlist
covid company genetic cell treatment potential therapy study
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Published: 2023-11-28 (Crawled : 13:00) - prnewswire.com
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: -3.42%
H: 3.24%
C: 2.95%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.93%
arct-154 covid vaccine approved mrna
Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: -9.08%
H: 0.0%
C: 0.0%
tnx-102 management covid pharmaceuticals topline results study
Axcella Granted Patent for Long COVID Fatigue Treatment
Published: 2023-08-29 (Crawled : 14:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: 221.81%
H: 39.94%
C: 23.97%
patent covid granted treatment
Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 2.05%
H: 10.0%
C: 2.0%
tnx-102 covid treatment pharmaceuticals study
Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID
Published: 2023-07-06 (Crawled : 14:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -1.49%
H: 1.24%
C: -2.62%
covid authorization
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
Published: 2023-06-30 (Crawled : 18:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
| Email alert
Add to watchlist
fda covid test application
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
Published: 2023-06-20 (Crawled : 20:00) - globenewswire.com
LMDX | $0.016 -15.0% 130M
|
|
| O: 30.46%
H: 17.17%
C: -2.98%
covid approval rsv
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Published: 2023-06-15 (Crawled : 22:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 1.74%
H: 1.71%
C: -1.95%
fda covid vaccine
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
Published: 2023-05-12 (Crawled : 13:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 1.46%
H: 3.55%
C: -6.32%
covid vaccine authorization
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
Published: 2023-04-17 (Crawled : 14:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -6.4%
H: 10.83%
C: -0.54%
axa1125 covid
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Published: 2023-04-17 (Crawled : 12:00) - biospace.com/
NNVC | $1.1 -6.38% 0.0% 22K
|
Health Technology
|
| O: 9.4%
H: 14.84%
C: 11.19%
drug candidate covid trials
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
Published: 2023-04-13 (Crawled : 12:00) - biospace.com/
TLSA | News | $0.6698 4.66% 4.45% 600K
|
Health Technology
|
| O: 0.0%
H: 5.88%
C: 5.88%
covid life foralumab treatment sciences
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Published: 2023-02-21 (Crawled : 15:00) - globenewswire.com
EFTR | $1.645 -7.58% -8.21% 200K
|
|
| O: -42.99%
H: 54.67%
C: 43.67%
treatment covid trial therapeutics positive
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
Published: 2023-02-15 (Crawled : 23:00) - biospace.com/
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -1.27%
H: 1.27%
C: -4.32%
axa1125 fda clearance covid
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
Published: 2023-02-06 (Crawled : 16:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 10.0%
H: 0.76%
C: -9.09%
fda covid solutions approval authorization molecular influenza
Global Times: Connected in recognition: Foreign ambassadors signal a welcome for China's optimized, responsible COVID policy
Published: 2023-01-11 (Crawled : 11:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: 23.79%
H: 0.0%
C: 0.0%
global covid
More Relief Coming for Long COVID Sufferers from Health Advance Inc
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
WNBD | $0.0002 0.0% 4.9M
|
n/a
|
| O: 16.67%
H: 0.0%
C: 0.0%
HADV | $0.0039 -13.89% 70K
|
n/a
|
| O: 5.26%
H: 10.0%
C: -39.0%
covid health
BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID
Published: 2022-10-05 (Crawled : 22:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.3%
H: 0.0%
C: -9.09%
treatment covid life contract
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
Published: 2022-09-15 (Crawled : 14:00) - biospace.com/
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: -5.57%
H: 2.16%
C: -21.61%
covid-19 treatment quantum covid trial leap
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.